Neetu Chandra Sharma

Experts say COVID-19 should not be dismissed as just another seasonal flu. While widespread immunity has reduced the severity of infection, the virus continues to hospitalise and kill vulnerable people.

Dr. Reddy's Laboratories reported a weak first quarter as net profit fell 69% year-on-year, hit by lower sales of its blockbuster cancer drug lenalidomide and a one-time provision related to a semaglutide API issue. Revenue declined 6%, although the company said its underlying base business continued to deliver double-digit growth across key markets. Business Today TV speaks to M V Ramana, Chief Executive Officer, Global Generics, Dr. Reddy's Laboratories, on the earnings, growth drivers, semaglutide strategy and the outlook ahead.

Dr. Reddy's Laboratories reported a weak first quarter as net profit fell 69% year-on-year, hit by lower sales of its blockbuster cancer drug lenalidomide and a one-time provision related to a semaglutide API issue. Revenue declined 6%, although the company said its underlying base business continued to deliver double-digit growth across key markets. Business Today TV speaks to M V Ramana, Chief Executive Officer, Global Generics, Dr. Reddy's Laboratories, on the earnings, growth drivers, semaglutide strategy and the outlook ahead.

Hospital chain says higher occupancy, acquisitions and expansion into new markets will drive growth; July 29 IPO to leave it virtually debt-free.

Delhi-based dermatologist Dr Deepali Bhardwaj explains the science behind healthy skin, separating medical evidence from popular skincare trends.

Storage, green fuels and domestic manufacturing will drive the next phase of India’s clean energy transition, says Sumant Sinha, Founder, Chairman and CEO of ReNew.

Sun Pharmaceutical Industries reported consolidated revenue growth of 10.1% year-on-year in the first quarter of FY27, driven by strong growth in its India business and innovative medicines portfolio. India formulation sales rose 16%, while global innovative medicines sales increased 12.8%. EBITDA margin stood at 28.9%, while adjusted net profit rose 3.1%.The company also said the proposed Organon acquisition has received shareholder approval and remains on track to close in Q4, FY27. During the quarter, Sun Pharma received approvals for semaglutide in India, Brazil and South Africa. Business Today TV speaks to Jayashree Satagopan, CFO, Sun Pharmaceutical Industries Ltd, on the company’s quarterly performance, growth drivers, India business, innovation pipeline and the Organon acquisition.

Biocon reported a steady start to FY27, with total income rising 9 per cent year-on-year to 4,391 crore rupees, while EBITDA stood at 902 crore rupees and net profit came in at 141 crore rupees. Growth was led by the biopharma business, with biopharma revenue rising 17 per cent, driven by momentum from recent biosimilar and generic product launches across key markets. The company also strengthened its manufacturing capabilities with regulatory approval for its insulin fill-finish facility in Malaysia and said it expects growth momentum to accelerate through the year.Business Today TV speaks to Shreehas Tambe, CEO & Managing Director, Biocon Limited, on the company's first-quarter performance, growth drivers, biosimilars strategy, manufacturing expansion and outlook.

Lupin reported a strong start to FY27, with sales rising 33.3% year-on-year to ₹8,217 crore. EBITDA increased 42.8% to ₹2,580 crore, while profit after tax grew 16% to ₹1,417 crore. The quarter was driven by robust growth across the US, India, other developed markets and emerging markets, along with continued improvement in profitability. Business Today TV speaks to Ramesh Swaminathan, Executive Director, Global CFO and Head – IT and API Plus SBU, Lupin Limited, about the company's Q1 FY27 performance, growth across key markets, product pipeline, R&D investments, US business, India outlook and the outlook for the rest of FY27.

Wockhardt has returned to profit in Q1 FY27, reporting a PAT of ₹107 crore against a loss of ₹108 crore a year earlier. Revenue rose 26% to ₹929 crore, while EBITDA increased 86% to ₹188 crore.The company has also launched the Wockhardt Antibiotic Academy, a platform focused on antimicrobial resistance, antibiotic stewardship and scientific exchange among clinicians. Wockhardt says around 10 lakh patients die annually in India from multidrug-resistant infections.Business Today TV speaks to Dr Habil Khorakiwala, Founder Chairman, Wockhardt, on the company’s return to profit, its growth strategy, novel antibiotics, antimicrobial resistance and the commercial opportunity in infectious diseases.